Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Carbohydrate (i.e., saccharide radical containing) DOAI

Subclass of:

514 - Drug, bio-affecting and body treating compositions

514001000 - DESIGNATED ORGANIC ACTIVE INGREDIENT CONTAINING (DOAI)

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
514042000 N-glycoside 2793
514025000 O-glycoside 1208
514054000 Polysaccharide 858
514053000 Dissacharide 104
514062000 Glucosamine or derivative 44
514024000 S-glycoside 43
Entries
DocumentTitleDate
20130045931PRODUCTION AND USE OF ANTIBACTERIAL, ANTIPROLIFERATIVE, AND ANTIPHYTOPATHOGENIC BENZANTHRACENES - The invention relates to a compound of the general structure (I), where R is a hydrogen atom (H) or an unsubstituted, monosubstituted, or polysubstituted C02-21-2013
20090318369BIOMARKERS FOR ALZHEIMER'S DISEASE AND METHODS USING THE SAME - The present invention provides various biomarkers of Alzheimer's Disease (AD). The present invention also provides various methods of using the biomarkers, including methods for diagnosis of AD, methods of determining predisposition to AD, methods of monitoring progression/regression of AD, methods of assessing efficacy of compositions for treating AD, methods of screening compositions for activity in modulating biomarkers of AD, methods of treating AD, as well as other methods based on biomarkers of AD.12-24-2009
20130029922FORMULATIONS FROM NATURAL PRODUCTS, TURMERIC, PACLITAXEL, AND ASPIRIN - The invention provides novel compounds and formulations of turmeric oil, fish oil, aspirin and anti-cancer drugs (paclitaxel) having anti-inflammatory, analgesic and/or anti-cancer activity.01-31-2013
20080280836Anti-hypercholesterolemic biaryl azetidinone compounds - This invention provides cholesterol absorption inhibitors of Formula I:11-13-2008
20090075908Agent For Strengthening Calcium Containing Tissue and Use Thereof - The present invention has an object to provide an agent for strengthening calcium-containing tissues, which can be safely applied; and its use: The present invention solves the object by providing an agent for strengthening calcium-containing tissues, which comprises one or more flavones, flavonols, flavanones, flavanonols, anthocyanidins, flavanols, chalcones, and aurones.03-19-2009
20090149395NOVEL MACROCYCLIC POLYENE LACTAMS - The invention relates generally to novel macrocyclic polyene lactams and their analogs, to processes for the preparation of these novel macrocyclic polyene lactams, to pharmaceutical compositions comprising the novel macrocyclic polyene lactams; and to methods of using the novel macrocyclic polyene lactams to treat or inhibit various disorders.06-11-2009
20110195918METHOD FOR PRODUCING PECTIN HYDROLYSIS PRODUCTS - Methods for the production of pectin hydrolysis products, the pectin hydrolysis products produced in this manner, as well as their use are described.08-11-2011
20100048491DRUGS, FOODS OR DRINKS WITH THE USE OF ALGAE-DERIVED PHYSIOLOGICALLY ACTIVE SUBSTANCES - Medicinal compositions for treating, ameliorating or preventing diseases with sensitivity to 3,6-anhydrogalactopyranose represented by formula (1): 02-25-2010
20130035298PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF - The invention relates to the treatment or prevention of renal impairment and/or complications using a SGLT-2 inhibitor, for example in patients diagnosed with metabolic disorders and related conditions.02-07-2013
20130035299ANTIMICROBIAL COMPOSITION BASED ON BOTANICAL EXTRACTS FROM OIL PALM VEGETATION LIQUOR - The present invention provides an antimicrobial composition comprising compounds extracted from the vegetation liquor of the palm oil milling process has been suggested. This composition is rich in antioxidants and exhibits enhanced antimicrobial activity and bactericidal effect against a number of micro-organisms.02-07-2013
20130040902METHOD FOR ENHANCING MILK QUANTITY AND QUALITY - This invention provides a method for enhancing quantity and quality of milk in mammals, while improving their health. The method particularly enables to substantially increase global milk production and improve economy of the dairy industry, without negatively affecting the wellbeing of dairy cattle.02-14-2013
20100099631Novel Use - The present invention relates to the use of the combined oral administration of caffeine with carbohydrate for increasing the rate of muscle glycogen resynthesis after strenuous exercise.04-22-2010
20100099630Method for improving ventilatory efficiency - This invention is a method of improving the function of the pulmonary arm of the cardiac-pulmonary axis by the administration of a pharmaceutical or nutritional supplement to a patient in which the function of the pulmonary arm is suboptimal, but not as a sequella of dysfunction of the cardiac arm. The exemplar patient is one suffering from chronic obstructive pulmonary disease. The preferred pentose is D-ribose, to be administered chronically.04-22-2010
20100041616Formulations for Nonsurgical Exogenous Crosslink Therapy - Improved methods and compositions for the treatment of native tissues with crosslinkers are provided. The methods and compositions will find particular use in increasing resistance to tearing, fissuring, rupturing, and/or delamination.02-18-2010
20090124561DIHYDROXYPHENYL COMPOUNDS AND GLUCOSIDE COMPOUNDS THEREOF - A skin cosmetic composition comprising the compound represented by the following formula (1):05-14-2009
20100137228DRUGS, FOODS OR DRINKS WITH THE USE OF ALGAE-DERIVED PHYSIOLOGICALLY ACTIVE SUBSTANCES - Medicinal compositions for treating, ameliorating or preventing diseases with sensitivity to 3,6-anhydrogalactopyranose represented by formula (1): 06-03-2010
20100069310GLUCOPYRANOSYL-SUBSTITUTED BENZYL-BENZONITRILE DERIVATES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE - Glucopyranosyl-substituted benzyl-benzonitrile derivatives of general formula (I) as defined according to claim 03-18-2010
20090042810AMPK Deficient Animals, Screening Methods, And Related Therapeutics And Diagnostics - The invention provides transgenic 02-12-2009
20090305998HSP90 INHIBITORS - The invention relates to HSP90 inhibiting compounds consisting of the formula:12-10-2009
20090305997USE OF A GALACTOSE-DERIVED C-GLYCOSIDE COMPOUND AS AN AGENT FOR ACTIVATING AND REGULATING CUTANEOUS IMMUNITY - The present invention relates to a novel galactose derivatives of general formula (I) and to their use as agents for stimulating the immune system of the skin and/or as immunoregulators, and for preparing a composition containing a cosmetically or pharmaceutically acceptable medium, intended in particular to prevent and/or limit the appearance of cutaneous immune imbalances, in particular related to environmental stresses.12-10-2009
20090305996USE OF NON-DIGESTABLE SACHARIDES FOR GIVING AN INFANT THE BEST START AFTER BIRTH - A food or supplement for pregnant women comprising water soluble, non-digestible saccharides is described. The composition is used to improve the flora and/or immune system of the pregnant women, to improve the immune system of the infant and to improve the intestinal flora of the infant after birth.12-10-2009
20130072448Drug Combination Comprising A Glycolysis Inhibitor And A Tyrosine Kinase Inhibitor - A drug combination comprising at least one inhibitor of tyrosine kinase and at least one inhibitor of glycolysis. The drug combination may be used in the treatment of proliferative disorders, such as liver or colon cancer. The inhibitor of tyrosine kinase may be an inhibitor of at least one of the tyrosine kinases Fer and FerT.03-21-2013
20120309698HIV Integrase Inhibitors - The disclosure generally relates to the novel compounds of formula I, including their salts, which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.12-06-2012
20110015141METHOD FOR TREATING CANCERS HAVING HIGH GLUCOSE REQUIREMENTS EMPLOYING AN SGLT2 INHIBITOR AND COMPOSITIONS THEREOF - Methods are provided for treating cancers that have high glucose requirements and that express SGLT2 at levels higher than normal cells, such as metastatic cancers, for example, metastatic lung cancers, employing an SGLT2 inhibitor alone or in combination with a cytotoxic agent and to a composition containing a combination of an SGLT2 inhibitor and a cytotoxic agent.01-20-2011
20130059801FATTY ACID AMIDES, COMPOSITIONS AND METHODS OF USE - The invention relates to fatty acid amides; compositions comprising an effective amount of a fatty acid amide; and methods for treating or preventing cancer, a metabolic disease or a neurodegenerative disease comprising the administration of an effective amount of a fatty acid amide.03-07-2013
20130059802BORON-CONTAINING SMALL MOLECULES - This invention relates to compounds useful for treating fungal infections, more specifically topical treatment of onychomycosis and/or cutaneous fungal infections. This invention is directed to compounds that are active against fungi and have properties that allow the compound, when placed in contact with a patient, to reach the particular part of the skin, nail, hair, claw or hoof infected by the fungus. In particular the present compounds have physiochemical properties that facilitate penetration of the nail plate.03-07-2013
20120115799PHARMACEUTICAL FORMULATIONS - The present invention relates to formulations including compounds of Formula (I),05-10-2012
20120115798METHOD FOR IMPROVING THE IMMUNITY OF A COMPANION ANIMAL - A method of improving the immunity of a companion animal. The method can include administering to the companion animal a glucose anti-metabolite. The glucose anti-metabolite can be 2-deoxy-D-glucose; 5-thio-D-glucose; 3-O-methylglucose; 1,5-anhydro-D-glucitol; 2,5-anhydro-D-glucitol; 2,5-anhydro-D-mannitol; mannoheptulose; and mixtures and combinations thereof. The companion animal can be a dog or a cat. Improving the immunity can include altering the proliferative ability of T and B immune cells, and altering the relative distribution of immune cell phenotypes, for example.05-10-2012
20090005323Cathepsin K Inhibitors and Obesity - This invention relates to the treatment of obesity, the treatment of obesity related disorders, prevention of weight gam, prevention of weight regain or for weight maintenance by the use of a cathepsin K inhibitor as active ingredient, alone or in conjunction with other anti-obesity agents The invention also relates to the pharmaceutical compositions comprising cathepsin K inhibitor as active ingredient, pharmaceutically acceptable carriers or excipients, and optionally one or more anti-obesity agents.01-01-2009
201202385112-DEOXY-D-GLUCOSE FORMULATIONS FOR PREVENTION OR TREATMENT OF NEURODEGENERATIVE DISEASES - Pharmaceutical compositions containing 2-deoxy-D-glucose (2-DG) and methods of use for promoting neurological health and prevention of age-related neurodegeneration, such as Alzheimer's disease (AD), have been developed. The compositions may be formulated such that the composition, or the compound when release from the composition, crosses the blood-brain-barrier and promote neurotrophism and neuroprotection mechanisms in the brain. 2-DG can be administered alone or in combination with one or more additional therapeutic, diagnostic, and/or prophylactic agents. The compositions described herein can be administered orally, enterally, transdermally, transmucosally, intranasally or parenterally, in a dosage effective to prevent or alleviate neuronal damage, effect neuronal regeneration or sustain viability, increase expression of anti-apoptotic proteins, and/or decrease indicators of Alzheimer's Disease. The formulations can be formulated for daily, sustained, delayed or weekly/monthly administration.09-20-2012
20120238510CRYSTALLINE FORM OF BENZYLBENZENE SGLT2 INHIBITOR - Provided are crystalline forms of a compound having an inhibitory effect on sodium-dependent glucose cotransporter SGLT2. The invention also provides pharmaceutical compositions, methods of preparing the crystalline compound, and methods of using the crystalline compound, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT or SGLT2 inhibition.09-20-2012
20130165394AMINO ACID COMPOSITION FOR IMPROVING GLUCOSE TOLERANCE - Disclosed are compositions, including low-calorie beverages or liquids, comprising isoleucine, leucine, valine, cysteine, and methionine, in specified amounts, weight ratios, or both. The compositions are especially useful in treating individuals afflicted with impaired glucose tolerance or diabetes.06-27-2013
20090156511Agent for Enhancing Antiseptic Power - The present invention relates to a preservative efficacy-enhancing agent capable of allowing an antiseptic agent to exhibit a high preservative efficacy even when the antiseptic agent is used at a low concentration; a preservative efficacy-enhancing composition containing the same; and a method for enhancing a preservative efficacy of antiseptic agents. The present invention relates to: (1) a preservative efficacy-enhancing agent for antiseptic agents which includes an amphiphilic galactose derivative (A) as an effective ingredient; (2) a preservative efficacy-enhancing composition including 0.01 to 30% by mass of an amphiphilic galactose derivative (A) and 0.01 to 1.0% by mass of an antiseptic agent (B); and (3) a method for enhancing a preservative efficacy of an antiseptic composition which includes the step of allowing 0.01 to 30% by mass of an amphiphilic galactose derivative (A) to coexist with an antiseptic agent (B) in the composition.06-18-2009
20090131339COMPOUNDS HAVING NEUROPROTECTIVE PROPERTIES - The invention relates to the use of morin and mangiferin, the pharmaceutically acceptable salts, prodrugs and/or solvates thereof in the production of a pharmaceutical composition for the prevention and/or treatment of a neurodegenerative disease and symptoms associated with ageing, as well as to food compositions comprising said compounds.05-21-2009
20110281807PLANT DISEASE CONTROL AGENT COMPRISING D-TAGATOSE AS ACTIVE INGREDIENT, AND PLANT DISEASE CONTROL METHOD - A plant disease control agent comprising D-tagatose as an active ingredient; and a plant disease control agent comprising at least one member selected from the group consisting of saccharides and substances each having a bactericidal and/or fungicidal activity. The plant disease control agents are effective for the control of cucumber, grape and cabbage downy mildew, damping-off in seedlings caused by 11-17-2011
20100062988CHEWABLE SUSTAINED RELEASE FORMULATIONS - Sustained release compositions in tablet or multiparticulate forms comprising (a) an active ingredient, (b) a primary sustain release agent, (c) a wax-like agent, and (d) a bulking or spheronizing agent are provided. The compositions are chewable and/or taste masked. Oral dosage forms comprising such compositions and methods for preparing and using such compositions and dosage forms are also provided.03-11-2010
20110301103Methods of Treatment - The present disclosure provides a biochemical basis of nephrotic syndrome and provides and explanation for the observed proteinuria and other effects. As a result, the present disclosure provides method for treating and/or preventing nephrotic syndrome as well as methods of alleviating symptoms associated with nephrotic syndrome. The present disclosure further provides methods for reducing proteinuria in nephrotic syndrome and other disease states as discussed herein.12-08-2011
20100056463NOVEL COMPOSITIONS - The present invention relates to novel compositions comprising hydroxytyrosol and/or oleuropein (I) and at least one additional component e.g. selected from the group of ligustilide, oleuropein aglycone, magnolol, honokiol, genistein, resveratrol, EGCG, magnolia bark extract, cashew fruit extract and 03-04-2010
20080200401SCF Extract Containing Cardiac Glycoside - A supercritical fluid (SCF) extract of a cardiac glycoside-containing plant mass is provided. The extract can be included in a pharmaceutical composition containing an extract-solubilizing amount of solubilizer. Oleandrin is included within the extract when a cardiac glycoside-containing plant, such as 08-21-2008
20100249046NOVEL MANGIFERIN CALCIUM SALTS, THE METHOD FOR ITS PREPARATION AND ITS USE - The present invention relates to novel mangiferin calcium and its preparation and use. The mangiferin calcium can lower plasma insulin, glucose, lipid, also can improve the solubility and oral bioavailability of mangiferin.09-30-2010
20110294749DIAMINOPYRIMIDINECARBOXAMIDE DERIVATIVE - A compound which may be used for the prevention or treatment of respiratory diseases in which STAT 6 is concerned, particularly asthma, chronic obstructive pulmonary disease and the like is provided.12-01-2011
20110288037Pharmaceutical Composition for the Treatment of Pathologies Caused by the General Response of the Immune System - The present invention relates to a pharmaceutical composition consisting of amides of mono- and di-carboxylic acids and hydroxystilbenes, and may be used for the treatment of pathologies caused, sustained and/or characterised by an abnormal general response of the immune system, in both humans and animals.11-24-2011
20100035830Iron-Carbohydrate Complex Compounds - The invention provides an iron-carbohydrate complex compound which is characterized by a content of iron(II). The invention also provides processes for the preparation of the iron-carbohydrate complex compound and the use thereof for treatment of iron deficiency anaemias.02-11-2010
20100035829METHOD OF TREATING INTRAUTERINE INFLAMMATION - A method of treating intrauterine inflammation in a subject associated with intrauterine bacterial infection includes administering to the subject a therapeutically effective amount of a toll-like receptor 4 antagonist. The therapeutically effective amount administered to the subject is an amount effective in reducing intrauterine inflammation in the subject.02-11-2010
20100035828MILK OLIGOSACCHARIDE FOR STIMULATING THE IMMUNE SYSTEM - The present invention relates to methods and nutritional compositions for stimulating the immune system, particularly in subjects with an impaired immune system such as 5 infants, said method comprising administering a composition comprising sheep milk and/or short chain oligosaccharides.02-11-2010
20090099101Drugs, foods or drinks with the use of algae-derived physiologically active substances - Medicinal compositions for treating, ameliorating or preventing diseases with sensitivity to 3,6-anhydrogalactopyranose represented by formula (1):04-16-2009
20090099100Compositions and methods for treating amyloidosis - Therapeutic compounds and methods for modulating amyloid aggregation in a subject, whatever its clinical setting, are described. Amyloid aggregation is modulated by the administration to a subject of an effective amount of a therapeutic compound of the formula04-16-2009
20110269700GLUCOSIDE DERIVATIVES AND USES THEREOF - The present invention relates to compounds of formula I11-03-2011
20090099099Isoflavone Glycosides as Peroxisome Proliferator-Activated Receptor-alpha Modulator - A method of treating or preventing diseases related to modulation of PPAR-α in comprising administering to a human or other mammals in need of such treatment an effective amount of plant material derived from plants of the genera 04-16-2009
20120190631MATERIALS AND METHODS RELATING TO GLYCOSYLATION - Techniques to glycosylation are described, and more particularly to the production of glycosylation structures that are resistant to enzymatic degradation, thereby modulating one or more of their biological properties or those of therapeutic moieties incorporating them, and in particular to reacting activated carbohydrate substrates containing fluorine, such as 3-fluoro sialic acid compounds, with sugar acceptors to produce covalent conjugates of the sugar acceptor and one or more of the sialic acid compounds.07-26-2012
20100120702SOLID PREPARATION FOR DIALYSIS - The present invention provides a glucose decomposition-suppressed solid preparation for dialysis among powdery or granular preparations for dialysis containing acetate-free solid organic acids as pH adjusting agents. The present invention provides the solid preparation for dialysis containing electrolytes, glucose and pH adjusting agents characterized in that solid organic acids containing reduced amount of microparticles are used, and more specifically, characterized in that solid organic acids whose 20 or less percent of particles are 250 μm or less in diameter, or solid organic acids whose 10 or less percent of particles are 150 μm or less in diameter, are used. Preferably, the solid organic acid contained therein is citric acid.05-13-2010
20100087384JASMONATE BASED ASSAYS FOR IDENTIFYING COMPOUNDS THAT SELECTIVELY INHIBIT MITOCHONDRIAL BOUND HEXOKINASES - The present invention provides compositions comprising compounds that selectively bind to hexokinases thereby promoting dissociation of these enzymes from mitochondria, and methods of use of such compounds and compositions to induce cell death in diseases and disorders characterized by the high levels of mitochondrial bound hexokinase. The present invention further discloses methods and assays for detecting and identifying molecules having these activities.04-08-2010
20100120701Compositions and Methods For Engineering Probiotic Yeast - The invention provides compositions and methods for engineering probiotic yeast to display α(1,2) fucosylated glycans on their cell surface, and the use thereof in the prevention or treatment of infection.05-13-2010
20130023486PHENYL C-GLUCOSIDE DERIVATIVES, PREPARATION METHODS AND USES THEREOF - The present invention relates to a sodium glucose cotransporter 2 (SGLT2) inhibitor with a phenyl C-glucoside structure, its preparation method, a pharmaceutical composition containing the same, and its use in treating diabetes and preparing an anti-diabetes medicament. The invention provides a compound with the structure of general formula I and a pharmaceutically acceptable salt and prodrug ester thereof,01-24-2013
20110195917PHARMACEUTICAL COMPOSITION COMPRISING A GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATE - The invention relates to a pharmaceutical composition according to the claim 08-11-2011
20100081625METHODS FOR PREVENTING AND TREATING NEURODEGENERATIVE DISORDERS - The present invention relates to a method for treating, preventing or slowing, delaying or reversing progression of one or more neurodegenerative disorders in a patient in need thereof characterized by administering a glucopyranosyl-substituted benzene derivative, a tautomer, stereoisomer, mixture or salt thereof, as defined in claim 04-01-2010
20090286749Cosmetic Composition and a Process For Preparing Said Composition - The present invention relates to a cosmetic composition that provides prolonged moisturizing to the skin and a differentiated sensorial, and may be employed in various types of products. This cosmetic composition comprises olive esters, biosaccharide gum-1, a wetting agent of vegetable origin, an emollient of vegetable origin, a silicone and an oiliness adsorber. Further, the present invention relates to a process of preparing this cosmetic composition.11-19-2009
201102697017,2''-DEHYDRATE PUERARIN AND ITS SALTS, PREPARATION METHOD AND USE THEREOF - A 7,2″-dehydrate puerarin represented by formula (I) and salt derivatives thereof. The compounds are prepared from puerarin by intramolecular mitsunobu reaction. They are capable of shortening arrhythmia duration and prolonging coagulation time. They can be prepared into oral formulations or injections for treatment of cardiovascular and cerebrovascular diseases including arrhythmia, coronary heart disease, angina pectoris, myocardial infarction, and cerebral infarction.11-03-2011
20120295856FREDERICAMYCIN DERIVATIVES - The invention relates to novel fredericamycin derivatives, to drugs containing said derivatives or the salts thereof, and to the use of the fredericamycin derivatives for treating diseases, especially cancer diseases.11-22-2012
20080274984METHOD, COMPOSITION AND KIT FOR ANTIGENIC BINDING OF NORWALK-LIKE VIRUSES - A method for detecting a Norwalk-Like Virus (NLV) in a biological sample, comprising the steps of: obtaining a biological sample suspected of containing a NLV; contacting the biological sample with at least one human histo-blood group antigen to allow formation of a complex of the NLV with the antigen; and detecting the antigen-NLV complex. The antigen-NLV complex can be detected by contacting the NLV-antigen complex with a NLV antibody that binds at an epitope of the NLV, and detecting the NLV antibody. The invention also includes a method for identifying compounds, and the compounds, that can inhibit the binding between a Norwalk-Like Virus (NLV) and a histo-blood group antigen. The method includes the steps of contacting the NLV target with a compound; subsequently contacting the NLV with a standard compound that is known to be bound at a determinant binding site of the NLV; and determining whether the binding of the standard compound is decreased in the presence of the test compound, the decrease in binding being an indication that the test compound inhibits the binding activity of the NLV with the standard compound. In preferred embodiments, the standard compound is a histo-blood group antigen.11-06-2008
20080287372Use of Ketogenic Compounds for Treatment of Age-Associated Memory Impairment - This invention relates to the field of therapeutic agents for the treatment of Age-Associated Memory Impairment (AAMI). In particular, the present invention utilizes compositions comprising at least one compound capable of elevating ketone body concentrations in a mammal (e.g., ketogenic compounds), administered in an amount effective for treatment or prevention of loss of cognitive function caused by reduced neuronal metabolism in AAMI. In one embodiment, the composition includes medium chain triglycerides (MCT). In another embodiment, the compositions are administered in the presence of carbohydrate. The present invention also relates to oral dosage forms, in particular, a nutritional drink comprising at least one compound capable of elevating ketone body concentrations in a mammal.11-20-2008
20080293642C-Glycosylisoflavones Having Alkylaminoalkoxyl Substituent, Preparation and Use of the Same - The present invention relates to C-Glycosylisoflavones having alkylaminoalkoxyl substituent and pharmaceutically acceptable salts thereof, a process for the preparation thereof, pharmaceutical compositions comprising an effective amount of a compound of the formula (I), and to the use of these compounds or compositions for the treatment or prevention of cardio- and cerebrovascular diseases, in particular for the treatment of various cardiocerebral hypoxic-ischemic diseases, for the treatment or prevention of diabetes mellitus and complications thereof, and for the treatment or prevention of chemical poisoning, in particular alcoholism.11-27-2008
20080306011Method of Controlling the Proliferation of Vascular Endothelial Cells and Inhibiting Lumen Formation - [PROBLEMS] To find out a specific rare sugar having effects of inhibiting the proliferation of vascular endothelial cells and lumen formation and utilize these effects. To provide this rare sugar as a preventive/remedy for diseases with angiogenesis, a cosmetic or a functional food.12-11-2008
20080306012Polysaccharide-Derived Nitric Oxide-Releasing Carbon-Bound Diazeniumdiolates - The invention relates to compounds capable of releasing nitric oxide wherein the compounds comprise a saccharide and at least one nitric oxide-releasing diazeniumdiolate [N12-11-2008
20080312162Methods and Compositions for Enzyme-Specific Activation of Carbohydrate-Conjugated Prodrugs - Methods for the targeted activation of prodrugs by enzymes, which cleave a linkage between a carbohydrate conjugate and a drug. Means to target the activation of prodrugs to specific cells by linking the enzyme to an antibody molecule. Carbohydrate conjugates of geldanamycin.12-18-2008
20080300195METABOLIC IMPRINTING - The present invention generally relates to the field of nutrition. In particular the present invention relates to infant nutrition in the post natal period and in early life, more particular during the age period of 6-36 months or during a part thereof. One embodiment of the present invention is a kit of diet compositions for children during the age period of 6-36 months or during a part thereof, wherein the macronutrient content of the compositions is gradually changing in the form of a straight line from a composition that comprises about 40-50% energy from fat and about 40-49% energy from carbohydrates for children at the age of 6 months to a composition that comprises about 30-35% energy from fat and about 50-55% energy from carbohydrates for children at the age of 36 months, and its use to prevent obesity later in life.12-04-2008
20090264375INTRAOCULAR IRRIGATING SOLUTIONS AND METHODS FOR TREATING CORNEAL EDEMA - One aspect of the present invention relates to methods of treating corneal edema comprising contacting a cornea with an ophthalmic irrigating composition comprising histidine. In certain embodiments, the ophthalmic irrigating compositions contact the corneal endothelium. Another aspect of the present invention relates to ophthalmic irrigating compositions for treating corneal edema comprising histidine and optionally, calcium glycerophosphate and/or glutathione disulfide.10-22-2009
20100144652COMPOSITION COMPRISING A GLYCOLYTIC INHIBITOR AND A RING SYSTEM COMPRISING A SULPHAMATE GROUP FOR THE TREATMENT OF CANCER - The present invention provides a composition comprising (a) a glycolytic inhibitor (b) a compound comprising a ring system substituted with at least one of a suiphamate group and an alkoxy group; wherein (a) and (b) are different.06-10-2010
20090029927COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDENT GLUCOSE TRANSPORTER - The invention is directed to compounds of the formula (I) described herein, a pharmaceutically acceptable salt thereof, or a prodrug thereof, and pharmaceutical compositions and methods of treatment.01-29-2009
20090186833METHOD FOR PRODUCING PECTIN HYDROLYSIS PRODUCTS - Methods for the production of pectin hydrolysis products, the pectin hydrolysis products produced in this manner, as well as their use are described.07-23-2009
20090054351COMPOSITION FOR MODERATING ALCOHOL METABOLISM AND FOR REDUCING THE RISK OF ALCOHOL INDUCED DISEASES - The present invention is directed to a composition of matter, in particular a food composition, dietary or food supplementation, and pharmaceutical composition, respectively. The composition of matter reduces the risk of neuropathy, neurodegenerative diseases including late-onset Alzheimer's disease, and cancer, in particular of pancreatic, esophageal, oropharyngolaryngeal, liver, colorectal, lung and/or breast cancer, in particular the drug and/or alcohol induced risk of said diseases. In this respect, the present invention is also directed to a composition of matter; in particular a food composition, dietary or food supplementation, and pharmaceutical composition, respectively, which supports and/or moderates the alcohol degradation process within the human body.02-26-2009
20080318873CAMPTOTHECIN DERIVATIVES AS CHEMORADIOSENSITIZING AGENTS - Camptothecin-based compounds are useful for treating a neoplasm in mammalian subjects by administering such compound to the subjects in combination with radiotherapy, i.e., the treatment of tumors with radioactive substances or radiation from a source external to the subject. Camptothecin-based compounds are modified by positioning at least one electron-affinic group around the camptothecin structure to enhance their value in combination with radiotherapy. New Camptothecin-based compounds are disclosed that are useful for treating cancer by administering the novel compounds alone or in combination with radiotherapy.12-25-2008
20090325890USE OF GALACTOSE C-GLYCOSIDE DERIVATIVES AS PROTECTIVE AGENT AND/OR GAMA DELTA T LYMPHOCYTE ACTIVATOR - The present invention relates to the use of at least one galactose-derived C-glycoside of general formula (I):12-31-2009
20100004184Anti-hypercholesterolemic compounds - This invention provides cholesterol absorption inhibitors of Formula (I), and the pharmaceutically acceptable salts and esters thereof. The compounds arc useful for lowering plasma cholesterol levels, particularly LDL cholesterol, and for treating and preventing atherosclerosis and atherosclerotic disease events.01-07-2010
20090023665ANTIBIOTICS GE 81112 FACTORS A, B, B1, PHARMACEUTICALLY ACCEPTABLE SALTS AND COMPOSITIONS, AND USE THEREOF - The invention relates to an antibiotic substances of microbial origin, arbitrarily denominated antibiotic GE 81112 factor A, factor B1 and factor B, which is produced by fermentation of 01-22-2009
20100197611ALTERNATIVE AGENT WITH VITAMIN D-LIKE ACTIVITY AND AN IMPROVING AGENT FOR INTESTINAL FUNCTION - The present invention relates to an alternative agent with vitamin D-like activity or an improving agent for age-related depression of intestinal function, comprising a sugar-phosphate ester or a salt thereof, as an active ingredient.08-05-2010
20110230428CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF - Certain chemical entities are provided herein. Pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.09-22-2011
20090197820Compositions and Methods for Improving Cardiovascular Health - Compositions and methods for improving cardiovascular health in the elderly by delivering a selection of essential amino acids, phytosterols, stanols, and isoflavones, which may be supplemented with a low glycemic carbohydrate and/or a medium chain fatty acid.08-06-2009
20090197818Use Of Ribose for Recovery From Anaesthesia - D-Ribose is administered before and after general anaesthesia to reduce the time to recover from the effects of general anaesthesia. Preferably, pyrogen-free D-Ribose is administered intravenously during general anaesthesia and the interval post-anaesthesia before oral administration can be resumed. D-Glucose may be co-administered to reduce the effect of hypoglycemia that may be seen with D-Ribose administration.08-06-2009
20120077761COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF CORONARY HEART DISEASES - Disclosed herein are compounds and plant extracts, and methods for preventing or treating heart diseases, including coronary heart diseases. The compounds provided herein can be formulated into pharmaceutical compositions and medicaments that are useful in the disclosed methods. Also provided are the use of the compounds and extracts in preparing pharmaceutical formulations and medicaments.03-29-2012
20090247476MANNITOL AND/OR PROLINE FOR PREVENTION AND TREATMENT OF AGEING RELATED SYMPTOMS - The current invention provides new methods and means for the prevention and treatment of ageing-related symptoms and diseases. The invention discloses mannitol 5 and/or proline containing compositions that are particularly useful for the treatment of premature ageing related symptoms in mammalian subjects suffering from genetic defects in DNA damage response and genome maintenance pathways. Humans suffering from Cockayne syndrome (CS), Xeroderma pigmentosum (XP), combined XPCS, trichothiodystrophy (TTD), COFS (cerebro-oculo-facio-skeletal syndrome), 10 XFE disorder (Xpf-Erccl syndrome), Bloom Syndrome (BS), Werner Syndrome (WS), Ataxia telangiectasia (AT), Fanconi Anemia (FA), Hutchinson Guilford Progeria (HGP) may be treated with pharmaceutical compositions comprising mannitol and/or proline according to this invention.10-01-2009
20090105162SUBSTITUTED FUSED HETEROCYCLIC C-GLYCOSIDES - This invention relates to substituted fused heterocyclic C-glycosides, compositions containing them, and methods of using them, for example, for the treatment or prophylaxis of diabetes and Syndrome X.04-23-2009
20090221515MONOSACCHARIDE DERIVATIVES - The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds disclosed herein can be useful for inhibition and prevention of inflammation and associated pathologies, including inflammatory and autoimmune diseases such as bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection, psoriasis, inflammatory bowel disease, ulcerative colitis, acne, atherosclerosis, cancer, pruritis or allergic rhinitis. Pharmacological compositions containing the compounds of the present invention and the methods of treating bronchial asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, multiple sclerosis, type I diabetes, psoriasis, allograft rejection, inflammatory bowel disease, ulcerative colitis, acne, atherosclerosis, cancer, pruritis, allergic rhinitis and other inflammatory and/or autoimmune disorders, using the compounds are also provided.09-03-2009
20090253642MIMICKING THE METABOLIC EFFECTS OF CALORIC RESTRICTION BY ADMINISTRATION OF GLUCOSE ANTI-METABOLITES - Methods of maintaining and/or attenuating a decline in the quality of life of a mammal comprising the step of administering to the mammal a composition comprising an effective amount of mannoheptulose wherein the effective amount of mannoheptulose provides a dosage to the mammal on a daily basis from about 0.001 gram per kilogram of body weight of the mammal to about 1 gram per kilogram of body weight of the mammal.10-08-2009
20100152121Iodo-Hexose Compounds Useful to Treat Cancer - Methods of treating glioblastoma and pancreatic cancer are provided by the administration of a therapeutically effective amount of a iodo-hexose compound to a subject in need thereof. The subject disclosure includes methods of treating glioblastoma and pancreatic cancer comprising the administration of a therapeutically effective amount of a 2-deoxy-2-iodo-D-hexose compound including 2-deoxy-2-iodo-D-mannose, 2-deoxy-2-iodo-D-glucose, 2-deoxy-2-iodo-D-galactose, and/or 2-deoxy-2-iodo-D-talose to a subject in need thereof.06-17-2010
20100173853COMBINATION OF MONOSACCHARIDES WITH ASCORBIC ACID AND USE THEREOF - Composition containing a combination of at least one monosaccharide chosen from mannose, rhamnose and a mixture thereof, and of at least one additional compound chosen from ascorbic acid, an analogue thereof and a mixture thereof. The present invention also relates to the use of such a composition for combating the signs of ageing, and also to a device containing the composition.07-08-2010
20120196812PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF - The invention relates to the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia using a SGLT-2 inhibitor. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.08-02-2012
20100190727USE OF MONOSACCHARIDES AND COMPOSITION THEREFOR - The present invention relates to the use, especially the cosmetic use, of at least one monosaccharide chosen from mannose, rhamnose and a mixture thereof, for reducing or preventing the signs of ageing of the skin or its integuments. The present invention also relates to a cosmetic composition and a device containing it.07-29-2010
20100190726Novel Phyllanthus Extract - A method is described for producing an extract of 07-29-2010
20100184710Therapeutic Bifunctional Compounds - The invention generally relates to systems and methods for treating inflammatory and proliferative diseases, enabling treatment of MDR tumor cells by using a bifunctional compound that inhibits both fatty acid metabolism and glycolysis. Thus, the invention links a fatty acid metabolism inhibitor to a glycolysis inhibitor. More particularly, the invention provides novel bifunctional compounds that link a moiety having the functionality of an oxirane carboxylic acid compound to a moiety having the functionality a glucose derivative. In specific embodiments, the invention provides a bifunctional compound that links a moiety having the functionality of etomoxir to a moiety having the functionality of 2-deoxy-D-glucose.07-22-2010
20080214479Methods of mimicking the metabolic effects of caloric restriction by administration of mannoheptulose - A method of obtaining beneficial biological results associated with caloric restriction may be gained by administration of a composition containing at least one active agent which blocks metabolism of glucose as a source of energy in cells in glucose metabolism blocking effective amounts to an animal in need thereof.09-04-2008
20110059907Chiral Complexes of Ascorbic Acid with Natural Antioxidant and Anti-Inflammatory Ketones Including Aloe, Citrus, Ginger, and Mango for Skin and Hair Care - This invention relates to certain complexes of ascorbic acid and its derivatives with certain natural antioxidant and anti-inflammatory ketones for topical or oral application; said complexes having general chemical formula (I), its isomers, and salts thereof, including their optically active or racemic forms. This invention also relates to a method of treatment of skin condition, including dark skin, age spots, acne, inflammation, loss of cellular antioxidants, collagen loss with aging, loss of skin pliability, loss of skin suppleness, skin wrinkles, oxidation, damage from radiation, malfunction of matrix metalloproteases, malfunction of tyrosinases, damage from free radicals, photo-damage, nutritional deficiency, and combinations thereof;03-10-2011
20110059906Energy status of an individual by enhanced production of an endogenous fuel source - The present invention relates to a method of improving the energy status of an individual by enhancing the usage of lactate. Improved lactate usage is accomplished through a composition comprising lactate precursors, adrenergic receptor agonists and insulinotropic agents.03-10-2011
20090197819Compositions for improving and repairing skin - Compositions for improving the condition of the skin or for repairing damaged skin are disclosed. The compositions contain D-ribose as the active ingredient plus a penetrant to deliver D-ribose to the basal cells and dermis of the skin. Compositions further containing emollients and emulsifiers are disclosed.08-06-2009
20110130351GLYCOLIPID FRACTION FROM CYANOBACTERIA FOR TREATMENT OF DISEASES OF THE ORAL CAVITY - The present invention relates to the preparation and use of a glycolipid fraction from 06-02-2011
20090239812USE OF C7 SUGARS IN PREVENTION AND TREATMENT OF MYCOSES - The object of the invention is use of at least one C7 sugar to make a composition intended for prevention and/or treatment of mycoses selected from among the group constituted of candidoses and pityrosporoses. The C7 sugars are preferably a water soluble extract of avocado sugars.09-24-2009
20100216727Carbohydrate-metallocene-antimalarial conjugates - An antimalarial conjugate according to a non-limiting embodiment of the present invention may include a metallocene, a carbohydrate, and an antimalarial agent. The metallocene may include two cyclopentadienyl rings bound to a central metal atom. The carbohydrate and the antimalarial agent may be appended to at least one of the cyclopentadienyl rings of the metallocene, wherein the antimalarial agent has therapeutic properties directed to treating and/or preventing malaria. The metallocene may be ferrocene, the carbohydrate may be glucose, and the antimalarial agent may be chloroquine.08-26-2010
20110112043METHOD OF UTILIZING PHYSIOLOGICAL ACTIVITY OF RARE SACCHARIDE AND COMPOSITION CONTAINING RARE SACCHARIDE - A method of utilizing the physiological activity of a rare saccharide, wherein physiological-activity sensitive cells are treated with the rare saccharide to modify the function of the cells. A composition containing, as an active ingredient, a rare saccharide which is introduced into physiological-activity sensitive cells and has an effect of modifying the function of the cells. The cells are human cells. The composition is a functional food, a drug, or a cosmetic. The rare saccharide is a rare saccharide belonging to aldose and/or ketose. The aldose is D-allose, and the cells are selected from the group consisting of cancer-cell proliferation inhibitory activity sensitive cells and active-oxygen production inhibitory activity sensitive cells. The ketose is D-psicose, and the cells are selected from the group consisting of chemokine secretion inhibitory activity sensitive cells, microglia migration inhibitory activity sensitive cells, and hypoglycemic activity sensitive cells.05-12-2011
20100144651NOVEL GLUCOPYRANOSE ESTERS AND GLUCOFURANOSE ESTERS OF ALKYL- FUMARATES AND THEIR PHARMACEUTICAL USE - The present invention relates to novel glucofuranose esters and glucopyranose esters of alkyl-fumarates. The esters are suitable for use as active substances in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders.06-10-2010
20110112041Treatment of Male-Pattern Baldness by Local Induction of the Metabolic Defect of Fabry Disease - Compositions comprising inhibitors of lysosomal enzyme alpha-galactosidase A and their use to favor hair growth or to prevent hair loss are disclosed in the instant invention. The topical use of the composition of the instant invention directly inhibits scalp enzyme activity and is used in the treatment for male pattern baldness (androgenic alopecia) in men and women.05-12-2011
20100210569Mitochondria-targeting antioxidant therapeutics - The instant invention constitutes an unique subject matter as a whole which has four individual aspects: (1) a class of chiral, non-racemic, synthetic carnitinoid analog carrier molecules which constitute biocompatible transport compounds not found in nature; (2) a subsequently formed, mitochondria-targeting, coupled antioxidant-carrier complex comprising an antioxidant reversibly attached to and releasable from the synthetic carrier molecule; (3) a method for introducing a biologically active antioxidant into the interior of mitochondria of a living cell for subsequent reaction with such reactive oxygen species may then be present; and (4) a system for delivering a biologically active antioxidant to the interior of mitochondria within a living cell.08-19-2010
20100137229Method Of Enhancing Lysosomal Alpha-Galactosidase A - A method of enhancing the activity of lysosomal α-Galactosidase A (α-Gal A) in mammalian cells and for treatment of Fabry disease by administration of 1-deoxy-galactonojirimycin and related compounds.06-03-2010
20120142617ANTIVIRAL THERAPEUTIC AGENTS - The invention provides compounds of Formula I:06-07-2012
20120142618KETOGENIC SACCHARIDES - A novel ketogenic compound is provided having general formula (R(OCH(CH06-07-2012
20090247475METHODS AND COMPOSITIONS RELATING TO PHARMACOGENETICS OF DIFFERENT GENE VARIANTS IN THE CONTEXT OF IRINOTECAN-BASED THERAPIES - The present invention is directed to methods and compositions for determining the presence or absence of polymorphisms within an ABCC2, UGT1A1, and/or SLCO1B1 gene and correlating these polymorphisms with activity levels of their gene products and making evaluations regarding the effect on their substrates, particularly those substrates that are drugs. In addition, there are methods and compositions of evaluating the risk of an individual for developing toxicity or adverse event(s) to an ABCC2, UGT1A1, and/or SLCO1B1 substrate. In some embodiments, the invention concerns methods and compositions for determining the presence or absence of ABCC2 3972C>T variant and predicting or anticipating the level of activity of ABCC2 and determining dosages of an ABCC2 drug substrate, such as irinotecan, in a patient. Such methods and compositions can be used to evaluate whether irinotecan-based therapy, or therapy involving other ABCC2 substrates, may pose toxicity problems if given to a particular patient or predicting their efficacy. Alterations in suggested therapy may ensue based on genotyping results.10-01-2009
20090181903Compositions and Methods for Increasing Muscle Mass, Strength, and Functional Performance in the Elderly - Compositions and methods for increasing muscle mass, strength, and functional performance in the elderly by delivering a selection of amino acids, carnitine, and carboydrates with a low glycemic index.07-16-2009
20120270814COMPOSITIONS AND METHODS FOR REDUCING OR PREVENTING OBESITY - Compositions useful for weight management in an animal are disclosed. The compositions comprise one or more isoflavones or isoflavone metabolites, and in some embodiments include conjugated linoleic acid, and/or L-carnitine. Also disclosed are methods useful for weight management in an animal utilizing compositions comprising one or more isoflavones, conjugated linoleic acid, and/or L-carnitine. Preferably, the compositions and methods employ a combination of one or more isoflavones, or a combination of one or more isoflavones in conjunction with conjugated linoleic acid, and L-carnitine.10-25-2012
20130137646METHODS OF TREATMENT, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF - The invention relates to methods for preventing, slowing the progression of, delaying or treating metabolic disorders induced in patients by the treatment with neuroleptic agents comprising administering to the patients an SGLT2 inhibitor.05-30-2013
20090069252C-GLYCOSIDE DERIVATIVES AND SALTS THEREOF - The present invention provides C-glycoside derivatives and salts thereof, wherein B ring is bonded to A ring via —X— and A ring is directly bonded to the glucose residue, and it is usable as a Na03-12-2009
20100331267USE OF CYCLOHEXANEHEXOL DERIVATIVES IN THE TREATMENT OF ALPHA-SYNUCLEINOPATHIES - The present invention relates to methods for treating α-synucleinopathies, methods for modulating of assembly, folding, accumulation, oligomerization, rate of aggregation, oligomerization and clearance of proteins of fragments comprising α-synuclein aggregates in a subject, by administering a medicament comprising a therapeutically effective amount of a cyclohexanehexyl derivative. More specifically, the invention provides medicaments comprising at least one cyclohexanehexyl derivative of formula (III) or (IV) useful in improving neuron, glia and oligodendrocyte function, for slowing the degeneration and death of neurons, glial cells and oligodendrocytes in the brain and treating synucleinopathies such as Parkinson's disease. These medicaments are formulated for oral and parenteral administration. Formulae (III), (IV).12-30-2010
20110009347COMBINATION THERAPY FOR THE TREATMENT OF DIABETES - The present invention is directed to co-therapy and methods for the treatment and prevention of glucose-related disorders such as Type 2 diabetes mellitus and Syndrome X. The present invention is further directed to pharmaceutical compositions for the co-therapy and methods described herein.01-13-2011
20100152122OLIGO-GULURONATE AND GALACTURONATE COMPOSITIONS - The invention provides a pharmaceutical composition comprising a macromolecular drug and an oligoguluronate or oligogalacturonate, e.g., having a number average degree of polymerization in the range 5 to 18, a guluronate (or galacturonate) fraction (F06-17-2010
20110003758Inhibitors of Glycolysis Useful In the Treatment of Brain Tumors - Provided herein are methods of treating brain tumors by administering a therapeutically effective amount of a compound of the Formulas I or II to a patient in need thereof.01-06-2011
20110021446COMPOSITIONS AND METHODS FOR FEEDING POULTRY - Feed supplements for poultry raised using a rapid growth regimen are disclosed herein. The supplements include D-ribose in an amount effective to improve the resistance to cardiomyopathy in the poultry. Methods for feeding poultry are also disclosed herein.01-27-2011
20090312274Nyasol and Analogs Thereof for the Treatment of Estrogen Receptor Beta-Mediated Diseases - Estrogenic compositions comprising nyasol and analogs thereof are provided. Also provided are methods of using said extracts to achieve an estrogenic effect, especially in a human, e.g. a female human. In some embodiments, the methods include treatment of climacteric symptoms. In some embodiments, the methods include treatment of estrogen receptor positive cancer, such as estrogen responsive breast cancer. In some embodiments, the methods include treatment or prevention of osteoporosis.12-17-2009
20100240601Coordination Complexes, Pharmaceutical Solutions Comprising Coordination Complexes, and Methods of Treating Patients - A coordination complex having a physiologically acceptable pK09-23-2010
20100222285METHOD OF CONTROLLING THE PROLIFERATION OF VASCULAR ENDOTHELIAL CELLS AND INHIBITING LUMEN FORMATION - A specific rare sugar having effects of inhibiting the proliferation of vascular endothelial cells and lumen formation is disclosed. This rare sugar is provided as a preventive/remedy for diseases with angiogenesis, a cosmetic or a functional food. The proliferation of vascular endothelial cells is controlled utilizing the vascular endothelial cell proliferation-controlling effect of D-mannose, D-allose, 2-deloxy-D-glucose, 3-deoxy-D-glucose, L-sorbose, 2-deoxy-D-ribose and/or 2-deoxy-L-ribose. Lumen formation of vascular endothelial cells is inhibited by utilizing the vascular endothelial cell lumen formation-inhibiting effect of D-allose, D-altrose, D-glucose, D-talose, L-allose, 2-deloxy-D-glucose, 3-deoxy-D-glucose, D-ribose, L-ribose, 2-deoxy-D-ribose and/or 2-deoxy-L-ribose.09-02-2010
20100056462MEDICAL COMPOSITION FOR PROMOTION OF SKIN REGENERATION - The present invention provides a medical composition which, in autotransplantation which is the only method that can induce the epithelialization even in a widespread full-thickness skin defect, enables the fixation of an autotransplantation skin graft in a simple manner and can increase the efficiency of epithelialization to promote the regeneration of the skin. The present invention elates to a medical composition comprising a photo-crosslinkable chitosan derivative and an amino acid and/or a saccharide. The amino acid is preferably an essential amino acid, and the saccharide is preferably a neutral saccharide selected from glucose, galactose, mannose and fucose.03-04-2010
20110077213METHOD FOR TREATING AND PREVENTING KIDNEY STONES EMPLOYING AN SGLT2 INHIBITOR AND COMPOSITION CONTAINING SAME - Methods are provided for treating and/or preventing kidney stones, employing an SGLT2 inhibitor alone, or in combination with a supply of carbohydrate, and/or in combination with a diuretic agent. Additionally, compositions comprising an SGLT2 inhibitor, optionally with a supply of carbohydrate, and/or a combination of an SGLT2 inhibitor and a diuretic agent are provided in the instant invention and are provided for use in the inventive methods.03-31-2011
20120149654HUMIC SUBSTANCES AND USES THEREOF IN AGRO-ENVIRONMENT - The present invention relates to the two main categories of humic substances, humic acids and fulvic acids and their use for hindering the propagation and/or contamination with prion infectivity both in agricultural and environmental systems.06-14-2012
20110071094(D)-ALLOSE INDUCING PROGRAMMED CELL DEATH IN HORMONE REFRACTORY PROSTATE CANCER LINES - The present disclosure relates allose inducing programmed cell death in hormone refractory prostate cancer cell lines. More particularly, the present disclosure relates to a D-allose inducing programmed cell death in hormone refractory prostate cancer cell line of DU145 in dose-dependent manner by repressing cell growth and inhibiting cell cycle as well as by reducing expression of caspase-3 and poly (ADP-ribose) polymerase (PARP).03-24-2011
20110152206THERAPEUTIC COMBINATIONS FOR USE IN NEOPLASIA - The invention features compositions and methods that are useful for the treatment of neoplasia (e.g., breast cancer) by increasing DNA damage and reducing base excision repair (BER).06-23-2011
20110077212THERAPEUTIC USES OF SGLT2 INHIBITORS - Provided are methods of using one or more SGLT2 inhibitors, independently or in combination, for treating edema or reducing fluid retention. The invention also provides methods of using one or more SGLT2 inhibitors for the preparation of a medicament for treating edema or fluid retention. Methods are also provided for treating diabetes with an amount of one or more SGLT2 inhibitors and one or more PPAR-gamma agonists.03-31-2011
20120065151Substances Mixture, Use and Infusion Solution - The present disclosure relates to a substance mixture, wherein the substance mixture contains ribose, alanine, nicotinic acid and ascorbic acid.03-15-2012
20120065150Neuroprotective effects of 2DG in Traumatic Brain Injury - This invention provides methods for reducing the extent and progression of traumatic brain injury and its deleterious sequellae specifically cognitive decline, post-traumatic epilepsy, post-traumatic stress disorder, and other adverse consequences depending on the progression of the initial injury, comprising administering to a TBI victim in need thereof a therapeutically-effective amount of an antiglycolytic compound, particularly 2-deoxyglucose (2-DG) or glycolysis-inhibiting analogs thereof. The invention also provides pharmaceutical compositions of 2-DG or glycolysis-inhibiting analogs thereof for use in the methods of the invention.03-15-2012
20110009348CARBOHYDRATE GEL - The present invention generally relates to the field of nutrition, in particular performance nutrition. In particular, the present invention relates to a novel carbohydrate gel comprising glucose and fructose in a ratio in the range of 3:1 to 1:1. The carbohydrate gel of the present invention can be used to treat or prevent problems with the gastrointestinal tract while allowing for an enhanced blood sugar maintenance and/or an increased exogenous carbohydrate oxidation.01-13-2011
20090281046Cyclopropanated Carbohydrates - Disclosed are cyclopropanated carbohydrate compounds of formulas I and II:11-12-2009
20110212905CRYSTALLINE FORM OF 1-(BETA-D-GLUCOPYRANOSYL)-4-METHYL-3-[5-(4-FLUOROPHENYL)-2-THIENYLMETHYL]- BENZENE HEMIHYDRATE - A novel crystal form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate, and having favorable characteristics, is characterized by its x-ray powder diffraction pattern and/or by its infra-red spectrum.09-01-2011
20100004185EXTRACTS DERIVED FROM SUGAR CANE AND A PROCESS FOR THEIR MANUFACTURE - An extract derived from sugar cane having GI or burn rate reducing characteristics wherein the extract comprises a mixture of one or more polyphenols, one or more carbohydrates, one or more minerals and one or more organic acids.01-07-2010
20110152205APPLICATION OF PUERARIN IN THE PREPARATION OF P2X3 MEDIATED DRUGS FOR PAIN/NERVOUS SYSTEM DISEASES - The invention relates to the new usage of puerarin in the field of pharmaceutical products, in other words, it relates to the application of puerarin in the preparation of drugs for P2X06-23-2011
20120202755FOLIAMANGIFEROSIDES, PREPARATION METHOD AND USE THEREOF - Foliamngiferosides having the general formula (I) are disclosed, wherein R is H or —OCH. The preparation method of the compounds, pharmaceutical compositions comprising the compounds as the active ingredients, the use of the compounds and the pharmaceutical compositions for inhibiting the activity of α-glucosidase are also disclosed.08-09-2012
20090082284Oil-in-Water Emulsions and Cosmetic Compositions Containing the Emulsions - Oil-in-water emulsions of at least one non-ionic emulsifier; at least one anionic co-emulsifier; an oil component having a polarity of at least 20 mN/m or a mixture of oil components wherein at least 75 weight-% of the oils constituting the mixture have a polarity of at least 20 mN/m; 6 to 35 weight-% of water based on the total weight of the emulsion; and wherein the total amount of emulsifier(s) is between 4 and 20 weight-%, based on the total weight of the emulsion are disclosed. Cosmetic compositions which contain the emulsions are also disclosed.03-26-2009
20110178032Monoglyceride of Acetoacetate and Derivatives for the Treatment of Neurological Disorders - This invention relates to methods of using the monoglyceride of acetoacetate and metabolic precursors for the treatment, prevention, inhibition or alleviation of neurological diseases associated with neuronal hypometabolism, such as Alzheimer's disease, Parkinson's disease, Friedreich's Ataxia (FRDA), GLUT1-deficient Epilepsy, Leprechaunism and Rabson-Mendenhall Syndrome, Coronary Arterial Bypass Graft (CABG) dementia, anesthesia induced memory loss, age associated memory impairment (AAMI), Traumatic Brain Injury (TBI), Huntington's disease and many others.07-21-2011
20110053869METHODS AND COMPOSITIONS FOR INHIBITING PROGRESSION TO CHRONIC CARDIAC FAILURE - The present invention is provides methods and formulations for preventing or ameliorating progression to chronic heart failure subsequent to cardiac stress, including as a consequence of myocardial infarction (MI), coronary artery disease, hypertension, cardiomyopathy, myocarditis, valvular regurgitation, severe lung disease, and/or severe anemia of chronic disease, by administration of one or more rate-limiting precursors to the synthesis of ATP. In one embodiment the ATP precursor is a pentose selected from one or more of ribose, D-ribose, ribulose, xylitol, xylulose, and a 5-carbon precursor of ribose.03-03-2011
20110053868L-SUGAR COLON CLEANSING AGENT AND USES THEREOF - Disclosed is L-glucose monohydrate and compositions thereof. Also disclosed are methods for making L-glucose monohydrate and compositions thereof. Further disclosed are methods for colonic cleansing using L-sugars, such as L-glucose monohydrate, and compositions and kits useful for colonic cleansing.03-03-2011
20110053867L-SUGAR COLON CLEANSING AGENT AND USES THEREOF - Disclosed is L-glucose monohydrate and compositions thereof. Also disclosed are methods for making L-glucose monohydrate and compositions thereof. Further disclosed are methods for colonic cleansing using L-sugars, such as L-glucose monohydrate, and compositions and kits useful for colonic cleansing.03-03-2011
20100298244COMPOSITION FOR THE PREVENTION AND THE TREATMENT OF HELICOBACTER PYLORI INFECTION - The disclosed item is a composition comprising catechins and sialic acid to provide an effective prevention and treatment for 11-25-2010
20100179097Use of kauranes compounds in the manufacture of medicament - This invention relates to the use of kauranes compounds having the structure of formula (I) in the manufacture of a medicament for treating and preventing the diseases such as coronary heart disease, cerebral apoplexy, cerebral ischemia and rhythm disturbance etc. The present compounds also have obvious protective effect against cerebral infarction and cerebral injure from ischemia, in which: R07-15-2010
20110178033GLUCOPYRANOSYL-SUBSTITUTED PHENYL DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE - Glucopyranosyl-substituted benzene derivatives of general formula I07-21-2011
20100160243COMPOUNDS AND METHODS FOR ENHANCING ERYTHROPOIESIS - Compounds and methods for enhancing erythropoiesis. The compound contains a chemical structure of the formula (I) indicated below, in which R is a glucosyl group. In addition to having an erythropoiesis effect, the compound of the formula (1) is effective in enhancing erythropoietin formation, and increasing kidney function and expression of hepatocyte growth factor. The method includes the step of administering an effective amount of the compound of the formula (I) to a subject in need thereof and thereby results in an enhancement of erythropoiesis.06-24-2010
20100029576Diazoxide for the treatment of Friedreich's Ataxia - A pharmaceutical preparation treats Friedreich's ataxia and treats or prevents pathologies related thereto. In particular, the pharaceutical preparation concerns the use of diazoxide or 7-chloro-3-methyl-4H-1,2,4 benzothiadiazine 1,1-dioxide, in combination with glucose and/or leucine, for the treatment of Friedreich's ataxia (FRDA) and for the treatment or prevention of pathologies related thereto.02-04-2010
20100022460C-PHENYL GLYCITOL COMPOUND - Provided is a novel C-phenyl glycitol compound that may serve as a prophylactic or therapeutic agent for diabetes by inhibiting both SGLT1 activity and SGLT2 activity, thereby exhibiting a glucose absorption suppression action and a urine glucose excretion action. A C-phenyl glycitol compound represented by Formula (I) below or a pharmaceutically acceptable salt thereof or a hydrate thereof01-28-2010
20100022461Novel Derivatives of Cyclic Compound And The Use Thereof - Disclosed is tonovel cyclic derivatives having potent inhibiting effect on melanin formation and skin hyper-pigmentation activity with no adverse response to skin. They can be used as the therapeutics for treating and preventing the skin disease caused by over-reproduced melanin.01-28-2010
20110118196ANTI-PHTHIRAPTERA TREATMENT COMPOSITIONS - Liquid ovicidal/pediculicidal compositions for eradication of ectoparasites, such as head-lice and other phthiraptera, are disclosed. The compositions comprise 5-50 weight percents of a film-forming carbohydrate and optionally 1-10 weight percents of oil, and are washable within a time period of 1-5 minutes from hair at a length of less than 60 cm in a stream of water of at least 5 liters per minute and a temperature lower than 40° C. Hair care formulations such as shampoos, conditioners, mousses, gels and the likes containing such an ovicidal/pediculicidal composition are further disclosed. Also disclosed are methods preparing and using the compositions and formulations.05-19-2011
20080312163Treatment of pulmonary hypertension with carbonic anhydrase inhibitors - This disclosure relates generally to methods and pharmaceutical compositions useful in treating pulmonary hypertension. In one embodiment, for example, the disclosure provides a method for treating pulmonary hypertension comprising administering a therapeutically effective dose of a carbonic anhydrase inhibitor to a patient in need of treatment. The disclosure finds utility in the fields of medicine and pharmacology.12-18-2008
20110015140ANTI-DIABETES COMPOSITION CONTAINING CHICORIC ACID AND/OR ONE OF THE METABOLITES THEREOF - The present invention relates to the use of chicoric acid and/or at least one of these metabolites selected among mono-caffeoyl-tartaric acid and/or m-hydroxyphenylpropionic acid, and/or 4-vinylcatechol and/or 4-ethylcatechol for manufacturing a composition intended for prevention or treatment in an insulin-resistant patient or hypoinsulinemia and/or associated pathologies.01-20-2011
20090118201BENZYLBENZENE DERIVATIVES AND METHODS OF USE - Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT inhibition.05-07-2009
20090149396DERIVATIVE OF GLUCOSE AND VITAMIN F, COMPOSITIONS COMPRISING IT, USES AND PREPARATION PROCESS - An O-acyl product derived from glucose which may be obtained by partial or total esterification of glucose and of vitamin F, comprising a mixture of esters, for example, monoesters, of glucose and of at least one acid chosen from linoleic acid, oleic acid, palmitic acid and stearic acid, compositions, for example, cosmetic and pharmaceutical compositions, comprising this novel derivative, and their use for improving the condition of head hair and/or other hairs, and, for example, for reducing and/or impeding the loss of head hair and/or other hairs, and/or for inducing and/or stimulating hair growth, as well as a process for preparing O-acyl derivatives mainly in position 6 of glucose, comprising preparing a mixed anhydride by reacting a carboxylic acid with a trimethylacetyl halide, followed by reacting said mixed anhydride formed with glucose.06-11-2009
20100069311MEDICAMENT COMPRISING A REDUCING ALKYL-SUGAR MONOMER FOR THE TREATMENT OF INFLAMMATORY DISORDERS - The invention relates to a medicament comprising at least one reducing alkyl-sugar monomer having a hydroxyl function which is substituted by an alkoxy radical at C03-18-2010
20090286750USE OF RIBOSE IN LESSENING THE CLINICAL SYMPTOMS OF ABERRANT FIRING OF NEURONS - A method for treating a mammal suffering from a condition caused by aberrant neuron firing is disclosed herein. The method includes administering (e.g., orally administering) to the mammal (e.g., a human patient) in need thereof a therapeutically effective amount of a composition including D-ribose.11-19-2009
20090209474NOVEL USES FOR DRUGS TARGETING GLUTAMINE SYNTHETASE - The present invention relates to novel therapeutic uses of tianeptine, salts, isomers, pro-drugs, metabolites and structural analogs thereof. Furthermore, the present invention relates to the use of tianeptine, salts, isomers, pro-drugs, metabolites and structural analogs thereof, in obtaining methods of screening and of developing drugs. Finally, the present invention relates to the novel therapeutic use of other glutamine synthetase (GS) ligands and to the use of these ligands in obtaining methods for screening and developing drugs.08-20-2009
20100240600Anti-Norovirus Agent and Composition Containing the Same - Provided is an anti-norovirus agent that has high norovirus-inactivating activity and is safe for the human body, and an anti-norovirus composition that contains the anti-norovirus agent and is useful for disinfection and infection control against the norovirus. The anti-norovirus agent includes, as an active ingredient, an extract from a plant of the genus 09-23-2010
20100197610FRUCTOSE 1, 6 BISPHOSPHATE - A NOVEL ANTICONVULSANT DRUG - The present invention concerns methods and compositions for preventing one or more epileptic seizures in an individual by delivering fructose-1,6-bisphosphate to the individual. In certain cases, an additional therapy for epilepsy is provided to the individual.08-05-2010
20090312273Compositions compromising Dimethyl Sulfoxide (DMSO) - The invention relates generally to compositions comprising dimethylsulfoxide (DMSO) and associated compounds in combination with one or more of the following: fructose 1,6-diphosphate, L-arginine, L-lysine, L-aspartate, and urea. Methods for treating traumatic brain injury, ischemic stroke, atherosclerosis, spinal cord trauma, and neurodegenerative illnesses are also provided.12-17-2009
20100298243COMBINATION THERAPY WITH SGLT-2 INHIBITORS AND THEIR PHARMACEUTICAL COMPOSITIONS - The present invention is directed to a pharmaceutical composition comprised of one or more SGLT-2 inhibitor compound(s) in combination with one or more therapeutic agents which is suitable for the treatment of metabolic disorders including type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance, hyperglycemia, postprandial hyperglycemia, overweight, obesity, including class I obesity, class II obesity, class III obesity, visceral obesity and abdominal obesity, and metabolic syndrome.11-25-2010
20110112042NOVEL FLAVONOL COMPOUNDS, A BIOACTIVE EXTRACT/FRACTION FROM ULMUS WALLICHIANA AND ITS COMPOUNDS FOR PREVENTION FOR TREATMENT OF OSTEO-HEALTH RELATED DISORDERS - The present invention provides a flavonol compound and a bioactive extract/fraction from 05-12-2011
20120040920OLIGOSACCHARIDE ALDONIC ACIDS AND THEIR TOPICAL USE - Methods for using compositions comprising oligosaccharide aldonic acids for general care, as well as for treatment and prevention, of various cosmetic conditions and dermatological disorders, including those associated with intrinsic and/or extrinsic aging, as well as with changes or damage caused by extrinsic factors; general care, as well as treatment and prevention of diseases and conditions, of the oral, and vaginal mucosa; for general oral care, as well as treatment and prevention of oral and gum diseases; and for wound healing of the skin. Methods may comprise using compositions comprising oligosaccharide aldonic acids and additional cosmetic, pharmaceutical or other topical agents to enhance or create synergetic effects.02-16-2012
20110319349Methods for Reducing Platelet Activation and for the Treatment of Thrombotic Events - Methods and compositions for the treatment or prophylaxis of a disorder associated with platelet activation or enhanced thrombin activity are provided, that include the administration of an effective amount of a compound of the formula:12-29-2011
20110319348BRASSINOSTEROIDS IN TREATING PROSTATIC HYPERPLASIA AND ANDROGENIC ALOPECIA - Provided are formulations containing brassinosteroids or their derivatives for treating androgen-associated conditions, such as prostate problems. Particularly formulations comprising at least one brassinosteroid or a derivative thereof are provided for treating benign prostatic hyperplasia or androgenic alopecia.12-29-2011
20120208775Sorbitol polyesters having liquid and solid domains - The present invention is directed to a series of sorbitol esters that have two different molecular weight ester chains, one solid and one liquid, which when combined into a single molecule make a polymer that is solid, but has very unique flow properties. These materials find applications as additives to formulations in personal care products where there is a desire to have a structured film (provided by the solid fatty group) and flow properties, (provided by the liquid fatty group). These compounds by virtue of their unique structure provide outstanding skin feel.08-16-2012
20110166086FLAVOR IMPROVING AGENT - Disclosed is a flavor improving agent that is a fraction derived from fruit juice or squeeze. A fraction wherein the amount of substance ratio between polyphenols and saccharides, the latter after acid hydrolysis of the fraction, (polyphenol/saccharide) is 0.1-10, and even more preferably, wherein the amount of substance ratio of the polyphenol and the saccharide before acid hydrolysis of the fraction (polyphenol/saccharide) is 1-100, and is used as a flavor improving agent. Such fraction are obtained with a method such as by a fruit juice or squeeze being absorbed onto a synthetic resin adsorbent and the adsorbed components being eluted by a solvent, or by extracting fruit juice or squeeze with ethanol. The flavor improving agent has flavor improving effects such as suppressing sourness, bitterness and astringency of foods and beverages, reducing harsh taste, contributing to a juice-like feel and contributing to a richness. In addition to foods and beverages, the flavor improving agent can also be added to pharmaceutical products or oral care products and the like, as well as to flavor composition.07-07-2011
20120015893FORMULATIONS CONTAINING SORBITAN CARBOXYLIC ACID ESTER - The invention relates to formulations for the washing and care of human or animal body parts, said formulations containing sorbitan carboxylic acid esters and characterized in that the carboxylic acid part of the sorbitain carboxylic acid ester is derived from a carboxylic acid containing between 6 and 10 carbon atoms and the sorbitan carboxylic acid esters have a hydroxyl count (OH count) of higher than 350. The invention also relates to the use of sorbitan carboxylic acid ester in washing or care formulations.01-19-2012
20120108526ANTI-MICROBIAL COMPOSITIONS - Antimicrobial compounds from 05-03-2012
20120122804SUBSTITUTED QUINOBENZOXAZINE ANALOGS - The present invention relates to quinobenzoxazines analogs having the general formula:05-17-2012
20120071423Heterotricyclic AMPA Receptor Antagonists for Treatment of Epilepsy, Pain, and Other Neurological Disorders and Diseases - Disclosed are heterotricyclic compounds, pharmaceutical compositions, methods of treatment, and methods for selectively antagonizing a glutamate receptor. The pharmaceutical compositions may include and the methods may utilize heterotricyclic compounds that are glutamate analogues which have specificity for AMPA receptors. The pharmaceutical compositions may be utilized to treat or prevent neurological diseases or disorders.03-22-2012
20110077214METHOD FOR TREATING HYPONATREMIA EMPLOYING AN SGLT2 INHIBITOR AND COMPOSITION CONTAINING SAME - Methods are provided for treating hyponatremia, employing an SGLT2 inhibitor alone, or in combination with a supply of carbohydrate, and/or in combination with a diuretic agent. Additionally, compositions comprising an SGLT2 inhibitor optionally with a supply of carbohydrate, and/or a combination of an SGLT2 inhibitor and a diuretic agent are provided in the instant invention and are provided for use in the inventive methods.03-31-2011
20110065656DOPAMINERGIC MIMETICS - A method is described for providing acute symptomatic relief to a subject with Parkinson's Disease (PD) or other CNS disorders resulting from dopamine deficiency in the brain comprising administering to said subject an amount of a ketogenic material sufficient to produce a ketosis in the subject sufficient to provide therapeutic benefit in such neurological disorders. Preferred materials produce a ketosis is such that the total concentration of acetoacetate and (R)-3-hydroxybutyrate in the blood of the subject is raised to between 0.1 and 30 mM.03-17-2011
20110065655THERAPEUTIC COMPOSITION TO TREAT LESIONS CAUSED BY HERPES SIMPLEX VIRUS - The present invention is generally directed toward therapeutic compositions for treating infections caused by Herpes Simplex Virus (“HSV”). The therapeutic compositions meet a long felt need in the art of providing a treatment for lesions that result from HSV that drastically reduce the duration of a cold sore when vesicles have already appeared and a treatment that will prevent the outbreak of a lesion and formation of vesicles when applied in the prodormal stage. The therapeutic compound comprises a mixture of Acyclovir (“ACV”), Penciclovir (“PCV”), and 2-Deoxy-D-Glucose (“2-DDG”). The therapeutic compositions of the present invention include multiple formulations of the three active ingredients and may also include inactive ingredients.03-17-2011
20090105161D-mannose contraceptives - The present invention concerns the use of D-mannose to prevent or inhibit uniting of sperm and egg/zygote in the conception process, both for specific target animals as well as general animal populations. It is emphasized that this abstract is provided to comply with the rules requiring an abstract that will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims. 37 CFR 1.72(b).04-23-2009
20110034402C-ARYL GLYCOSIDE COMPOUNDS FOR THE TREATMENT OF DIABETES AND OBESITY - This invention relates to a compound of generic formula (I): (I) as well as a pharmaceutically acceptable salt thereof a tautomer, optical isomer or a mixture of optical isomers in any proportion, in particular a mixture of enantiomers, and particularly a racemate mixture, in particular for use thereof as a drug, notably in the treatment of diabetes.02-10-2011
20120122805PESTICIDAL COMPOSITIONS - The invention disclosed in this document is related to the field of pesticides and their use in controlling pests. A compound having the following structure is disclosed.05-17-2012
20100093647MGMT INHIBITOR COMBINATION FOR THE TREATMENT OF NEOPLASTIC DISORDERS - A method of treating a neoplastic disease in a subject includes administering to neoplastic cells of the subject an MGMT inhibitor and at least one of an antimitotic agent or a DNA damaging agent.04-15-2010
20100093648TREATMENT OF MACULAR DEGENERATION-RELATED DISORDERS - The invention relates to compositions and methods for preventing or treating a macular degeneration-related disorder, comprising a scyllo-inositol compound or pharmaceutically acceptable salts thereof.04-15-2010
20120316121Materials and Methods for Modulating Arginine Metabolism - The present invention provides novel compositions and methods for their production and use in modulating arginine metabolism to treat biological conditions. The biological condition is preferably one associated with dysregulated arginine metabolism and/or abnormal endogenous levels of substances resulting from or involved in arginine metabolism. The subject invention provides compositions that modulate levels of arginine or levels of substances that are derived from arginine in vivo via pre-selected signal transduction/metabolic pathways. In one embodiment, compositions comprising arginine and a glycoside are provided. The compositions and methods of the invention are able to select and prompt a particular metabolic pathway in which the arginine is to be used as a substrate.12-13-2012
20090131338ANESTHESIA AROUSAL COMPOSITION - A method for facilitating postoperative awakening of patients from anesthesia does not depend on the experience of anesthesiologists. Also provided are an anesthesia arousal composition for use in this method and a preparation containing a bicarbonate ion that facilitates awakening from anesthesia. Specifically, the anesthesia arousal composition is provided in the form of infusion fluid. The method for controlling and facilitating awakening from anesthesia involves administering the anesthesia arousal composition. The present invention preferably provides an anesthesia arousal composition or an acidosis-correcting composition containing sodium bicarbonate as a major component that serves as a source of the bicarbonate ion, along with each or a combination of another electrolyte, glucose and an amino acid.05-21-2009
20110183926TREATMENT USING CONTINUOUS LOW DOSE APPLICATION OF SUGAR ANALOGS - Methods and uses of low dosage nonmetabolizable D-glucose analogs and mannose analogs such as 2-deoxy-D-glucose, 5-thio-D-glucose, 2-fluoro-2-deoxy-D-glucose, 2-chloro-2-deoxy-D-glucose, 2-bromo-2-deoxy-D-glueose, 2-deoxy-2-fluoro-mannose, 2-deoxy-2-chloro-mannose, 3-deoxy mannose, 4-deoxy mannose, and 2,3 didioxy mannose, for the treatment of tumors.07-28-2011
20110183927Compositions Comprising Sugar-Cysteine Products - The present invention provides compositions comprising sugar, cysteine, and/or sugar-cysteine products, methods of preparing the same, and/or using the same.07-28-2011
20120129793Antimicrobial Polyether and Polyol Compounds - The present application describes compounds of Formula I and Formula IA and as disclosed herein, that are useful as anti-microbial agents, including as antibacterial, disinfectant, antifungal, germicidal or antiviral agents.05-24-2012
20100222284COMPOSITION FOR INHIBITING THE ONSET OF ARTERIOSCLEROSIS AND INHIBITION METHOD - [Object] To provide a composition for inhibiting the onset of arteriosclerosis by using a rare sugar D-psicose and a method of inhibiting the onset of arteriosclerosis.09-02-2010
20120135943CELL PROTECTION IN DIALYSIS PATIENTS BY ADMINISTRATION OF A CREATINE COMPOUND - The invention relates to a dialysis solution for haemodialysis or peritoneal dialysis, said solution having a theoretical osmolarity within the range of from 250 to 550 mosm/L and a pH value within the range of from 4.9 to 8.0, said solution comprising a creatine compound and one or more electrolytes, wherein the concentration of the creatine compound is not more than 50 mM.05-31-2012
20100173854Microfluidized Oil-in-water Emulsions and Vaccine Compositions - This invention provides submicron oil-in-water emulsions useful as a vaccine adjuvant for enhancing the immunogenicity of antigens. The present invention also provides vaccine compositions containing an antigen combined with such emulsions intrinsically or extrinsically. Methods of preparing the emulsions and vaccines are also provided by the present invention.07-08-2010
20120214753PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION - The present invention provides a solid pharmaceutical composition comprising a cocrystal of (1S)-1,5-anhydro-1-[3-(1-benzothien-2-ylmethyl)-4-fluorophenyl]-D-glucitol and L-proline, in combination with crystalline cellulose, and also provides a method for producing the composition.08-23-2012
20120214752Glucosyl Stevia Composition08-23-2012
20120214751Glucosyl Stevia Composition08-23-2012
20100137230NEW PYRIDIN-2-ONE COMPOUNDS - The present invention relates to compounds of the formula (I) that are useful antimicrobial agents and effective against a variety of multi-drug resistant bacteria:06-03-2010
20100009924Compositions and methods for improving cardiovascular function - The present invention relates to methods for supplementing the diet of subjects suffering from cardiovascular disease. D-Ribose is given long term alone or in combination with vasodilators in order to improve or maintain the diastolic or systolic function of the subjects.01-14-2010
20100292175USE OF HYDROXYFLAVAN DERIVATIVES FOR TASTE MODIFICATION - The present invention primarily relates to the use of specific compounds of formula (I)11-18-2010
20120225832Amphiphilic Compositions and Methods for Preparing and Using Same - The invention relates to amphiphilic C-glycoside derivatives, to methods of using them and to processes for synthesizing them. Specifically, the invention relates to novel cyclic and linear enone-glycolipids and cyclic ketone-glycolipids.09-06-2012
20120264701USE OF D-RIBOSE FOR FATIGUED SUBJECTS - Low doses of D-ribose raise the level of fitness and lower the perception of fatigue in baby boomers aged 45-65 who perceive themselves as fatigued. The doses range from 0.100 grams to 3.0 grams, bid, for a total of 0.200 to 6.0 grams daily. Objective measures of cardiopulmonary parameters confirm the improvement of fitness and questionnaires confirm that quality of life and mental states are improved with D-ribose administration.10-18-2012
20120264700GLYCOSIDE DERIVATIVES AND USES THEREOF - The present invention provides a compound of formula I;10-18-2012
20120232025SAFENER DRUG COMBINATIONS FOR USE WITH NMDA ANTAGONIST DRUGS - Prolonged administration of subanesthetic dosages of ketamine, which suppresses activity at NMDA receptors, can provide a damaged central nervous system with an opportunity to use its innate healing processes to “reset” NMDA receptors which were pushed into an unwanted hyper-sensitized state by unusually high activity. However, such treatments can cause permanent brain damage, if the ketamine dosage is too heavy or prolonged. Certain types of “safener” drugs have previously been identified, which can block or at least reduce those unwanted side effects. It is disclosed that if two classes of safener drugs are combined, which will simultaneously suppress activity at both (i) muscarinic acetylcholine receptors, and (ii) the kainate and AMPA classes of glutamate receptors, those safener drug combinations can provide exceptionally potent and reliable safening activity, which can enable the safe use of potent NMDA antagonist drugs for a number of highly beneficial purposes.09-13-2012
20110003757PHARMACEUTICAL COMPOSITIONS FOR TREATING FATTY LIVER DISEASE - The present invention provides a pharmaceutical composition useful as a therapeutic agent for fatty liver disease. A pharmaceutical composition, which comprises (1S)-1,5-anhydro-1-[5-(azulen-2-ylmethyl)-2-hydroxyphenyl]-D-glucitol or a pharmaceutically acceptable salt thereof, (1S)-1,5-anhydro-1-[3-(1-benzothiophen-2-ylmethyl)-4-fluorophenyl]-D-glucitol or a pharmaceutically acceptable salt thereof, or alternatively, (1S)-1,5-anhydro-1-[4-chloro-3-(4-ethoxybenzyl)phenyl]-D-glucitol or a pharmaceutically acceptable salt thereof, more specifically such a pharmaceutical composition for treating fatty liver disease, such as nonalcoholic fatty liver disease in one embodiment, or nonalcoholic simple fatty liver and/or nonalcoholic steatohepatitis in another embodiment.01-06-2011
20100204161Substances and Pharmaceutical Compositions for the Inhibition of Glyoxalases and Their Use Against Bacteria - The present invention pertains to substances of the formula (I) wherein X is O or S; and R1-R4 are defined in the claims as inhibitors of glyoxalase I and/or II, pharmaceutical compositions comprising one or more compounds according to formula (I) and the use of one or more compounds according to formula (I) for the treatment of diseases associated with increased glycolytic metabolism. In one embodiment, the disease is a bacterial infection.08-12-2010
20110046077PROCESS FOR THE EXTRACTION OF MANGIFERIN AND ISOMANGIFERIN - The present invention relates to methods for extracting and isolating glycosyl xanthone derivatives, in particular mangiferin and isomangiferin, from plants of the Rubiaceae family, especially of the 02-24-2011
20110046076PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF - The invention relates to a pharmaceutical composition according to the claim 02-24-2011
20110237528COMPOSITIONS AND METHODS COMPRISING IMIDAZOLE AND TRIAZOLE DERIVATIVES - The present invention relates to compositions and methods for treating a disease in an animal, which disease is responsive to inhibiting of functional cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide by administering to a mammal in need thereof an effective amount of a compound defined herein (including those compounds set forth in Tables 1-3 or encompassed by formulas (I), (IA), (IB), (II), and (III)) or compositions thereof, thereby treating the disease. The present invention particularly, relates to a method of treating diarrhea and polycystic kidney disease.09-29-2011
20110237527SGLT-2 INHIBITORS, METHODS OF MAKING THEM, AND USES THEREOF - The present invention relates to compounds which are inhibitors of sodium dependent glucose co-transporter-2 (SGLT-2). These compounds are used in the treatment of various disorders, including diabetes, impaired glucose tolerance, insulin resistance, retinopathy, nephropathy, neuropathy, cataracts, hyperglycemia, hyperinsulinemia, hyperchlolesterolemia, elevated blood level of free fatty acids or glycerol, hyperlipidemia, hypertriglyceridemia, obesity, wound healing, tissue ischemia, atherosclerosis, and hypertension. These compounds and compositions are also useful for treating and preventing kidney stones, hyperuricemia, gout, and hyponatremia. Methods of making these compounds are also described in the present invention.09-29-2011
20110237526METHOD FOR THE PREPARATION OF A CRYSTALLINE FORM - The invention relates to a method for the preparation for a crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene. In addition the invention relates to a crystalline form obtainable by this method, to a pharmaceutical composition and to the use thereof for preparing medicaments.09-29-2011
20100234309Dendrimer Compositions - Amine compounds, amine polymers, crosslinked amine polymers and pharmaceutical compositions comprising the same may include polyhydroxy-containing cores that may be substituted with amine groups and may be used to treat hyperphosphatemia or to remove ions from the gastrointestinal tract of animals, including humans.09-16-2010
20120277170NUTRITIVE COMPOSITIONS AND METHODS OF USING SAME - The invention provides intradialytic parenteral nutrition (IDPN) compositions with low carbohydrate for the treatment of malnutrition in dialysis subjects. In some embodiments, the IDPN compositions are advantageous for the treatment of malnutrition in subjects who are diabetic or suffer from other glucose management related pathologies or subjects who benefit from strict fluid management.11-01-2012
20120329735LIFESPAN EXTENDING AGENT - A lifespan extending agent that is safe for animals, and can easily be ingested in a form that resembles foods. A lifespan extending method is also disclosed. In the lifespan extending agent, a rare sugar usable as a sweetener is contained as an active ingredient.12-27-2012
20120329732BENZYLBENZENE DERIVATIVES AND METHODS OF USE - Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT inhibition.12-27-2012
20120329733METHODS AND PRODUCTS RELATED TO METABOLIC INTERACTIONS IN DISEASE - The invention involves methods of regulating cell growth and division to control disease processes by manipulating mitochondrial metabolism and the expression of cell surface immune proteins. The invention also involves related compositions and screening assays.12-27-2012
20120329734Mixture and infusion or drink solution - The invention relates to a mixture, wherein the mixture contains ribose, alanine and glycine. The mixture furthermore can contain glutamine and one or more of the following substances: valine, leucine, isoleucine, 5-hydroxy-tryptophan, tryptophan, cysteine, serine. Alternatively or in addition, the mixture furthermore can contain asparagine, arginine, proline and lysine. The invention furthermore relates to a mixture which contains ribose, glycine, proline, lysine, arginine and asparagine.12-27-2012
20100168041COMBINATION OF MONOSACCHARIDES AND DESQUAMATING AGENTS, AND USE THEREOF - The present invention relates to a composition, especially a cosmetic and/or dermatological composition, containing, in a physiologically acceptable medium, a combination of at least one monosaccharide chosen from mannose, rhamnose and a mixture thereof, and of at least one desquamating agent. The present invention also relates to the use of such a composition, and to a device containing it.07-01-2010
20120101051NOVEL C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME - A novel C-aryl glucoside compound, or a pharmaceutically acceptable salt or a prodrug thereof having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney; and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly, diabetes, are provided.04-26-2012
201300124587-HYDROXY CHROMONES AS POTENT ANTIOXIDANTS - The present disclosure describes the identification and purification of 7-hydroxychromes that exhibit potent antioxidant activity. The present disclosure also includes methods for preventing and treating ROS mediated diseases and conditions and diseases and conditions associated with other oxidative processes. Included in this disclosure is an improved method to isolate and purify 7-hydroxychromones from plant sources.01-10-2013
20130012459COMPOSITION FOR INHIBITING THE ONSET OF ARTERIOSCLEROSIS AND INHIBITION METHOD - A composition for inhibiting the onset of arteriosclerosis is characterized by comprising D-psicose as an active ingredient for an antiatherogenic action. The antiatherogenic action as described above includes an action of inhibiting or reducing the expression of a chemokine or a cytokine related to arteriosclerosis in vivo and an action of promoting the expression of a receptor involved in the improvement of arteriosclerosis without affecting the expression of an arteriosclerosis inducer. This composition is used in the form of a product selected from the group consisting of sweeteners, seasonings, food additives, food materials, foods and drinks, health foods and drinks, drugs, quasi drugs and feeds blended with D-psicose and/or its derivative and/or a mixture thereof as the active ingredient. The method of inhibiting the onset of arteriosclerosis is a method of using the above composition.01-10-2013
20130012460TOPICAL PHARMACEUTICAL FORMULATIONS CONTAINING A LOW CONCENTRATION OF BENZOYL PEROXIDE IN SUSPENSION IN WATER AND A WATER-MISCIBLE ORGANIC SOLVENT - An aqueous formulation for topical application to the skin comprising water, a water-miscible organic solvent, and benzoyl peroxide, wherein the concentration of the organic solvent is sufficient to provide a stable suspension of benzoyl peroxide in the aqueous formulation without the inclusion of a surfactant in the formulation, wherein the ratio of concentrations of water and organic solvent in the formulation is sufficient to maintain the benzoyl peroxide in saturated solubility in the formulation following, application to the skin, and wherein the concentration of benzoyl peroxide in the formulation is less than 5.0% and at least 1.0% w/w. The formulation may further contain a chemical compound in addition to benzoyl peroxide that is effective in the treatment of acne. The aqueous formulations of the invention are useful in the treatment of acne and acne rosacea.01-10-2013
20100130435UTILIZATION OF THE FUNCTION OF RARE SUGAR AS PROMOTER FOR THE MIGRATION OF GLUCOKINASE FROM NUCLEUS TO CYTOPLASM - Screening for a glucokinase-activating substance among rare sugars and providing a composition for treating disordered conditions in association with glucokinase activity, the composition containing the glucokinase-activating substance as the active ingredient. A promoting agent of glucokinase transfer from nucleus to cytoplasm, the promoting agent containing D-psicose and/or D-tagatose as the active ingredient, or a composition for preventing the onset of disordered conditions in association with glucokinase activity or for therapeutically treating the disordered conditions, which is in a form selected from a group consisting of food additives, food materials, drinks and foods, health drinks and foods, pharmaceutical product and feeds in blend with D-psicose and/or D-tagatose as the active ingredient for use in preventing the onset of disordered conditions in association with glucokinase activity or for therapeutically treating the disordered conditions. The disordered conditions in association with glucokinase activity are selected from impaired glucose tolerance, type 2 diabetes mellitus, insulin resistance, abnormal lipidemia, the metabolic syndrome and obesity. The composition is in a pharmaceutical form, and contains D-psicose and/or D-tagatose together with one or more pharmaceutically acceptable carriers.05-27-2010
20100130434Hexose Compounds to Treat Cancer - Methods of treating glioblastoma and pancreatic cancer are provided by the administration of a therapeutically effective amount of a hexose compound to a subject in need thereof The subject invention includes methods of treating brain and pancreatic cancer comprising the administration of a therapeutically effective amount of a mannose compound to a subject in need thereof The subject invention further includes methods of treating the proliferation of tumors comprising the administration of a therapeutically effective amount of 2-FM to a subject in need thereof.05-27-2010
20130018005GLYCOSIDE DERIVATIVES AND USES THEREOF - The present invention provides a compound of formula I;01-17-2013
20080255057PRODRUG SUBSTITUTED BENZOXAZOLES AS ESTROGENIC AGENTS - This invention provides estrogen receptor modulators of formula I, having the structure10-16-2008
20090264374UTILIZATION OF ANTI-NEUROPATHIC PAIN EFFECT OF D-ALLOSE AND D-PSICOSE - [PROBLEMS] To control neuropathic pain produced by various mechanisms.10-22-2009
20080221044Composition for Inhibiting the Onset of Arteriosclerosis and Inhibition Method - [Object] To provide a composition for inhibiting the onset of arteriosclerosis by using a rare sugar D-psicose and a method of inhibiting the onset of arteriosclerosis.09-11-2008
20130137647NATURAL MEDICINAL COMPOUND - This invention refers to the sector of drugs intended for both human and animal use, and it particularly concerns a natural medicinal compound that contains a tannin-based vegetal active ingredient combined with carriers and with a synergic effect, wherein the vegetal active ingredient is natural chestnut extract (05-30-2013
20130172278NOVEL THIOPHENE DERIVATIVE AS SGLT2 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME - The present invention relates to a novel compound with thiophene ring having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney, and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes. The prevention also provides a method for preparing same, a pharmaceutical composition containing same, and a method for preventing or treating metabolic disorders, particularly diabetes.07-04-2013
20130172277PHARMACEUTICAL COMBINATION - Pharmaceutical combinations comprising a beta-3 adrenergic receptor agonist and a muscarinic receptor antagonist, and methods for their use are disclosed. Methods of using the pharmaceutical combinations for the treatment of one or more symptoms associated with overactive bladder, for example, frequency of urgency, nocturia, and urinary incontinence, are also disclosed.07-04-2013
20100279956Biomarkers For Fatty Liver Disease And Methods Using The Same - The present invention provides various biomarkers of fatty liver disease, including steatosis and steatohepatitis. The present invention also provides various methods of using the biomarkers, including methods for diagnosis of fatty liver disease, methods of determining predisposition to fatty liver disease, methods of monitoring progression/regression of fatty liver disease, methods of assessing efficacy of compositions for treating fatty liver disease, methods of screening compositions for activity in modulating biomarkers of fatty liver disease, methods of treating fatty liver disease, as well as other methods based on biomarkers of fatty liver disease.11-04-2010
20110218158DNA CYTOSINE DEAMINASE INHIBITORS - Cytosine deaminase inhibitors and methods for identifying inhibitors of the anti-retroviral activity of APOBEC3G are described.09-08-2011
20110212906C-LINKED GLUCURONIDE OF N-(4-HYDROXYBENZYL) RETINONE, ANALOGS THEREOF, AND METHODS OF USING THE SAME TO INHIBIT NEOPLASTIC CELL GROWTH - Compounds of the formula:09-01-2011
20110212904GALACTOSYLATED PRO-DRUGS OF NON-STEROIDAL ANTI-INFLAMMATORIES WITH IMPROVED PHARMACOKINETIC CHARACTERISTICS AND REDUCED TOXICITY OF THE STARTING DRUG - Pro-drugs of all non-steroidal anti-inflammatories with free acid function derivatized with an ester group, which have the general structural formula given below (I) where A is: aspirin, diflunisal, benorylate, ibufenac, diclofenac, indomethacin, sulindac, ketorolac, ibuprofen, naproxen, ketoprofen, fenoprofen, flurbiprofen, mefenamic acid, meclof enamic acid, flufenamic acid, niflumic acid, and where in the ester group R can be a sugar (amongst which aldose, or ketose pentose, or esose selected from a group of D- and L-enantioiuers of ribose, glucose, galactose, mannose, arabinose, xilose, allose, altrose, gulose, idose and talose and substituted derivatives thereof, such as glucosamine, galactosamine, N-acetyl glucosamine, N-acetyl galactosamine, N-acetyl ribosamine), a disaccharide, a trisaccharide or an oligosaccharide.09-01-2011
20110275576Carbohydrate-Cyclopamine Conjugates as Anticancer Agents - Various anticancer compounds are disclosed, including a series of carbohydrate-cyclopamine conjugates. These compounds include pyranose, furanose, and mannitol conjugates, linked through a 1,2,3-triazine ring to the nitrogen of cyclopamine. Methods for preparing these compounds, pharmaceutical compositions containing these compounds, and their use as anticancer agents are also disclosed.11-10-2011
20120277169NYASOL AND ANALOGS THEREOF FOR THE TREATMENT OF ESTROGEN RECEPTOR BETA-MEDIATED DISEASES - Estrogenic compositions comprising nyasol and analogs thereof are provided. Also provided are methods of using said extracts to achieve an estrogenic effect, especially in a human, e.g. a female human. In some embodiments, the methods include treatment of climacteric symptoms. In some embodiments, the methods include treatment of estrogen receptor positive cancer, such as estrogen responsive breast cancer. In some embodiments, the methods include treatment or prevention of osteoporosis.11-01-2012
20130150312TOPICAL ANTIVIRAL FORMULATIONS - The disclosure provides antiviral pharmaceutical compositions comprising one or more antiviral compounds and 2-deoxy-D-glucose in the form of lip-balms, creams and ointments. A specific embodiment discloses a lip-balm composition comprising acyclovir and 2-deoxy-D-glucose.06-13-2013
20130150313METHOD FOR DISINFECTING SURFACES - A malleable compound according to the invention for use as a disinfectant comprises water, 25 to 40% by weight of a solvent component comprising low-molecular, water-miscible alcohols, 1 to 10% by weight of an active bactericidal component, 3 to 6% by weight hydroxypropylated polygalactomannan with an etherification level of between 0.3 and 1.5 and 0.1 to 0.5% by weight boracic acid or an equivalent amount of boron ions.06-13-2013
20100317602NUTRITIVE COMPOSITIONS AND METHODS OF USING SAME - The invention provides intradialytic parenteral nutrition (IDPN) compositions with low carbohydrate for the treatment of malnutrition in dialysis subjects. In some embodiments, the IDPN compositions are advantageous for the treatment of malnutrition in subjects who are diabetic or suffer from other glucose management related pathologies or subjects who benefit from strict fluid management.12-16-2010
20120283198HALOGENATED DIDEOXY SUGAR DERIVATES, PREPARATION METHOD AND APPLICATION THEREOF - A halogenated dideoxy sugar derivative, having the following general structure I wherein X is halogen,11-08-2012
20120283197Compositions Comprising a Glucose Anti-Metabolite, BHA, and/or BHT - A composition including a glucose anti-metabolite, BHA, and/or BHT. The composition can be for a companion animal. The composition can be a nutritionally balanced pet food composition.11-08-2012
20130116202NGNA COMPOSITIONS AND METHODS OF USE - The present invention relates to the field of viral disorders, and in particular to the use of natural compounds to inhibit viruses and viral infection. Compositions comprising NGNA are provided for treating or preventing viral infections, such as those causing the common cold.05-09-2013
20120010160Rapidly Dissolving Oral Strip of Sugar for Hypoglycemia - A method of orally administering measured doses of sugar into the bloodstream for controlling glucose levels, particularly for those individuals with diabetes or those who experience difficulty maintaining healthy blood sugar levels. The method comprises providing packets of orally ingestible strips of a disintegrating matrix containing a dose of sugar to supplement food intake between meals or to rapidly increase glucose levels in an emergency situation. Hypoglycemia is a condition of low blood sugar (glucose) levels in the bloodstream, which can have varying reactions on individuals ranging from mild to severe. The disclosed matrix and method rapidly introduces sugar into the blood stream for combating a hypoglycemic reaction. The strips are easily deployable and quickly dissolve once placed on the tongue and mixed with saliva. They can be packaged in a small, easy-to-dispense, and transportable case that allows rapid use when a sugar supplement is required.01-12-2012
20120022007METHOD AND COMPOSITION FOR MODULATING CANONICAL WNT PATHWAY USING FOLATE AND INOSITOL - The canonical Wnt signaling pathway is implicated in many disorders including neural tube defects, limb malformations, and heart defects, developmental disorders associated with alcohol exposure (fetal alcohol syndrome) or exposure to bipolar medications (i.e. lithium), wound healing, and Alzheimer's disease. Elevated plasma homocysteine (HCy), which results from folate (folic acid, FA) deficiency, the mood-stabilizing drug lithium (Li), and alcohol (ethanol) are linked to the induction of human congenital heart and neural tube defects. FA supplementation ameliorates the observed developmental errors in the Li-HCy, or alcohol-exposed mouse embryos and normalized heart function. Li, HCy or Wnt3A suppress Wnt-modulated Hex and Islet-1 expression. FA protects from the gene misexpression that is induced by all three factors. Administration of myo-inositol with FA synergistically enhances the protective effect.01-26-2012
20130196935SYNTHETIC GLYCOAMINE COMPOUNDS - This disclosure is directed to synthetic glycoamine compounds and pharmaceutical compositions containing such compounds. The synthetic glycoamine compounds provided here can affect cell adhesion and induce apoptosis, and are useful in treating metastatic diseases and cancer.08-01-2013
20130196934COMPOSITION FOR PERINATAL AND NEONATAL STROKE - The present invention relates to a novel, non-toxic, prophylactic maternal nutraceutical composition for prevention, treatment, minimization or amelioration of brain damage from perinatal and/or neonatal stroke.08-01-2013
20130196936N-ACETYL MANNOSAMINE AS A THERAPEUTIC AGENT - The invention relates to compositions and methods for treating kidney and muscle dysfunction that involves use of therapeutic amounts of N-acetyl mannosamine.08-01-2013
20120040919EXFOLIATING COMPOSITION BASED ON CREAM OF TARTAR AND BICARBONATE - A solid exfoliating composition includes a surfactant, sodium bicarbonate, cream of tartar, and a granular exfoliant.02-16-2012
20120058959TOPICAL ANTIVIRAL FORMULATIONS - The disclosure provides novel topical antiviral pharmaceutical compositions comprising one or more antiviral compounds and 2-deoxy-D-glucose in the form of lip-balms, creams and ointments. A specific embodiment discloses a lip-balm composition comprising acyclovir and 2-deoxy-D-glucose.03-08-2012
20120071425USES OF MANNOSE-6-PHOSPHATE - There is provided the use of mannose-6-phosphate, or a salt, precursor or analogue thereof, for providing and/or maintaining a consistent skin colour, particularly to reducing redness of skin. There is also provided the use of mannose-6-phosphate, or a salt, precursor or analogue thereof, as a skin improvement agent for providing a cosmetic effect and mannose-6-phosphate, or a salt, precursor or analogue thereof, for use in treating normal or damaged skin, wherein damaged skin is skin that has been subject to epidermal and/or dermal damage.03-22-2012
20120071424PHARMACEUTICAL COMPOSITION USED IN PROPHYLAXIS OR TREATMENT OF HYPERPROLIFERATIVE SKIN CONDITIONS AND MALIGNANT MELANOMAS COMPRISING PACHASTRISSAMINE AS ACTIVE INGREDIENT - Disclosed is a novel use of phytosphingosine. More particularly, disclosed are a composition for preventing or treating hyper-proliferative skin diseases comprising pachastrissamine as an active ingredient, a use of pachastrissamine or a pharmaceutically acceptable salt thereof for preparing a preventing/therapeutic agent of hyper-proliferative skin diseases, and a method for treating hyper-proliferative skin diseases administering an effective amount of pachastrissamine or a pharmaceutically acceptable salt thereof to a subject in need thereof. The pachastrissamine inhibits the degradation of FoxO3a protein and increases the expression of FoxO3a protein. Thus, the inventive pharmaceutical composition has a preventing of treating effect on hyper-proliferative diseases by inducing apoptosis of hyper-proliferative cells and inhibiting the cell cycle. Accordingly, the disclosed composition, a use, and the method can be used for preventing or treating various hyper-proliferative skin diseases such as skin cancer or psoriasis.03-22-2012
20120077760NOVEL SALTS OF SITAGLIPTIN - The present invention relates to novel pharmaceutically acceptable salts of sitagliptin, to processes for their preparation and to pharmaceutical compositions containing them.03-29-2012
20120302514GLYCOCONJUGATES AND METHODS - Disclosed are compositions containing glycoconjugates and methods for making the functionalized glycoconjugates, which include (a) contacting a cell with a first monosaccharide, and (b) incubating the cell under conditions whereby the cell (i) internalizes the first monosaccharide, (ii) biochemically processes the first monosaccharide into a second saccharide, (iii) conjugates the saccharide to a carrier to form a glycoconjugate, and (iv) extracellularly expresses the glycoconjugate to form an extracellular glycoconjugate comprising a selectively reactive functional group. Methods for forming products at a cell further comprise contacting the functional group of the extracellularly expressed glycoconjugate with an agent that selectively reacts with the functional group to form a product. Subject compositions include cyto-compatible monosaccharides comprising a nitrogen or ether linked functional group selectively reactive at a cell surface and compositions and cells comprising such saccharides.11-29-2012
20120094941Mangiferin-Berberine Salt, Manufacturing Method and Use Thereof - The present invention provides a mangiferin-berberine salt and manufacturing method thereof. Otherwise, the present invention also provides the use of mangiferin-berberine salt as AMPK activator.04-19-2012
20120094940PROCESS OF PRODUCING SUGAR COMPOSITION COMPRISING DEFINITE AMOUNT OF TARGET HEXOSE AND HAVING SUGAR CONSTITUTION DIFFERENT FROM THAT OF STARTING SUGAR MATERIAL AND USE OF PRODUCED SUGAR COMPOSITION04-19-2012
20120094939ANTI-VIRAL COMPOUNDS, COMPOSITIONS AND METHODS - The present invention is directed to compounds of formulae (I) and (II) and pharmaceutically acceptable forms thereof; pharmaceutical compositions thereof; and methods of treating a viral infection, such as a hepatitis C virus (HCV) infection, by administering to a subject diagnosed with or being susceptible to the viral infection a compound of formulae (I) and (II), a pharmaceutically acceptable form thereof, or a pharmaceutical composition thereof. The present invention is also directed to high-throughput methods of identifying compounds able to modulate hepatitis C virus (HCV) replication activity.04-19-2012

Patent applications in class Carbohydrate (i.e., saccharide radical containing) DOAI

Patent applications in all subclasses Carbohydrate (i.e., saccharide radical containing) DOAI